3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
43
Rectal Neoplasms
12
Colonic Neoplasms
12
Neoplasm Metastasis
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Gallbladder Neoplasms
3
Colorectal Cancer Metastatic
3
Cholangiocarcinoma
3
Neutropenia
2
Neoplasms
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
mCRC
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Recurrence
1
Pretreated Metastatic Colorectal Cancer
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Carcinoma
1
Microsatellite-stable Colorectal Cancer
1
Metastatic Gastric Adenocarcinoma
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric and Gastroesophageal Junction Adenocarcinoma
1
Gastric Cancer Adenocarcinoma Metastatic
1
Gastric Adenocarcinoma
1
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Dihydropyrimidine Dehydrogenase Deficiency
×
trifluridine tipiracil drug combination
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled